Fuller & Thaler Asset Management Inc. boosted its position in shares of Azenta, Inc. (NASDAQ:AZTA - Free Report) by 27.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 747,801 shares of the company's stock after purchasing an additional 161,454 shares during the quarter. Fuller & Thaler Asset Management Inc. owned about 1.64% of Azenta worth $25,904,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AZTA. Farther Finance Advisors LLC increased its stake in shares of Azenta by 788.1% in the 1st quarter. Farther Finance Advisors LLC now owns 968 shares of the company's stock valued at $33,000 after acquiring an additional 859 shares during the last quarter. Quarry LP bought a new stake in shares of Azenta in the 4th quarter valued at about $110,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Azenta by 13,184.2% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,524 shares of the company's stock valued at $87,000 after acquiring an additional 2,505 shares during the last quarter. Sterling Capital Management LLC increased its stake in shares of Azenta by 39.8% in the 4th quarter. Sterling Capital Management LLC now owns 2,856 shares of the company's stock valued at $143,000 after acquiring an additional 813 shares during the last quarter. Finally, Deutsche Bank AG increased its stake in shares of Azenta by 28.5% in the 4th quarter. Deutsche Bank AG now owns 4,199 shares of the company's stock valued at $210,000 after acquiring an additional 931 shares during the last quarter. 99.08% of the stock is owned by institutional investors.
Azenta Stock Performance
NASDAQ AZTA traded up $1.71 during trading hours on Friday, reaching $31.55. 531,318 shares of the company's stock were exchanged, compared to its average volume of 719,375. The company's 50-day moving average is $31.32 and its two-hundred day moving average is $32.86. Azenta, Inc. has a one year low of $23.91 and a one year high of $55.63. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -13.04 and a beta of 1.59.
Azenta (NASDAQ:AZTA - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.13 by $0.06. Azenta had a positive return on equity of 1.35% and a negative net margin of 18.45%.The business had revenue of $143.94 million during the quarter, compared to analysts' expectations of $149.64 million. During the same period in the prior year, the business earned $0.14 EPS. Azenta's revenue for the quarter was up .0% compared to the same quarter last year. Research analysts predict that Azenta, Inc. will post 0.53 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on AZTA shares. Stephens started coverage on Azenta in a research note on Tuesday, July 22nd. They issued an "equal weight" rating and a $35.00 price target for the company. Raymond James Financial raised Azenta from a "market perform" rating to an "outperform" rating and set a $35.00 target price for the company in a research note on Wednesday, August 6th. Evercore ISI set a $33.00 target price on Azenta and gave the stock an "in-line" rating in a research note on Tuesday, August 5th. Finally, Needham & Company LLC lowered their target price on Azenta from $59.00 to $40.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Azenta presently has a consensus rating of "Hold" and an average target price of $35.75.
Read Our Latest Analysis on Azenta
Azenta Company Profile
(
Free Report)
Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.
See Also

Before you consider Azenta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Azenta wasn't on the list.
While Azenta currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.